+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Detection Sensitivity of Coronary Artery Stenosis by 99mTc-Sestamibi and 201T1 in Canine Models of Partial and Subcritical Stenosis

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          This study was designed to assess the sensitivity of the monocationic <sup>99m</sup>Tc-hexakis-2-methoxy, 2-methylpropylisonitrile (<sup>99m</sup>Tc-sestamibi) as compared to <sup>201</sup>T1 in the detection of regional myocardial blood flow deficits in dogs with different degrees of stenosis with or without dipyridamole. Regional myocardial distribution of <sup>99m</sup>Tc-sestamibi and <sup>201</sup>T1 was determined in mongrel dogs under different levels of left arterial descending coronary artery (LAD) stenosis (30–45, 60–70 and 100% flow reduction) as monitored with electromagnetic flow probes and radiolabeled microspheres. Both <sup>99m</sup>Tc-sestamibi and <sup>201</sup>T1 distribute in direct proportion to blood flow at all levels of stenosis (r<sup>2</sup> = 0.90–0.99). Quantitatively, both tracers underestimate the resting flow stenosis. The regional myocardial distribution for both <sup>99m</sup>Tc and <sup>20l</sup>Tl was also determined in subcritically stenosed mongrel dogs. This was produced by placing a balloon cuff around the LAD, infusing dipyridamole to peak hyperemic flow and immediately stenosing the LAD to basal flow. Stenosed to normal zone flow ratios were 0.68 ± 0.01 compared to <sup>99m</sup>Tc and <sup>201</sup>T1 ratios of 0.73 ± 0.04 and 0.80 ± 0.05, respectively. These data suggest that <sup>99m</sup>Tc is at least as sensitive as <sup>201</sup>T1 in the detection of different degrees of critical and subcritical coronary artery stenosis.

          Related collections

          Author and article information

          S. Karger AG
          12 November 2008
          : 79
          : 2
          : 135-145
          The Du Pont Merck Pharmaceutical Company, Diagnostic Imaging Division, Billerica, Mass., USA
          174871 Cardiology 1991;79:135–145
          © 1991 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 11
          Diagnostic Cardiology


          Comment on this article